FDA said to misuse "approvable" letters to delay decisions

06/7/2006 | Bloomberg Businessweek

Drugmakers complain the FDA is issuing "approvable" letters to gain more time to review submitted drugs, allowing the agency to avoid the six- to 10-month time limit for it to act. Some say the increase in the number of approvable letters is indicative of an overall slowdown at the agency.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC